» Articles » PMID: 40072105

A Cross-Sectional Exploratory Study of Rat Sarcoid (Ras) Activation in Women with and Without Polycystic Ovary Syndrome

Overview
Journal Cells
Publisher MDPI
Date 2025 Mar 12
PMID 40072105
Authors
Affiliations
Soon will be listed here.
Abstract

: Rat sarcoma (Ras) proteins, Kirsten, Harvey, and Neuroblastoma rat sarcoma viral oncogene homolog (KRAS, HRAS, and NRAS, respectively), are a family of GTPases, which are key regulators of cellular growth, differentiation, and apoptosis through signal transduction pathways modulated by growth factors that have been recognized to be dysregulated in PCOS. This study explores Ras signaling proteins and growth factor-related proteins in polycystic ovary syndrome (PCOS). : In a well-validated PCOS database of 147 PCOS and 97 control women, plasma was batch analyzed using Somascan proteomic analysis for circulating KRas, Ras GTPase-activating protein-1 (RASA1), and 45 growth factor-related proteins. The cohort was subsequently stratified for BMI (body mass index), testosterone, and insulin resistance (HOMA-IR) for subset analysis. : Circulating KRas, and RASA1 did not differ between PCOS and control women ( > 0.05). EGF1, EGFR, and EGFRvIII were decreased in PCOS ( = 0.04, = 0.04 and < 0.001, respectively). FGF8, FGF9, and FGF17 were increased in PCOS ( = 0.02, = 0.03 and = 0.04, respectively), and FGFR1 was decreased in PCOS ( < 0.001). VEGF-D ( < 0.001), IGF1 ( < 0.001), IGF-1sR ( = 0.02), and PDGFRA ( < 0.001) were decreased in PCOS compared to controls. After stratifying for BMI ≤ 29.9 kg/m, EGFR FGF8, FGFR1 VEGF-D, IGF1, and IGF-1sR differed ( < 0.05) though EGF1, EGFRvIII, FGF8, FGFR1, and VEGF-D no longer differed; after subsequently stratifying for HOMA-IR, only FGFR1, VEGF-D, IGF1, and IGF-1sR differed between groups ( < 0.05). : Several growth factors that activate Ras differ between women with and without PCOS, and when stratified for BMI and HOMA-IR, only FGFR1, VEGF-D, IGF1, and IGF-1sR differed; these appear to be inherent features of the pathophysiology of PCOS.

References
1.
Sircar A, Singh S, Xu-Monette Z, Coyle K, Hilton L, Chavdoula E . Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia. 2023; 37(10):2094-2106. PMC: 10539170. DOI: 10.1038/s41375-023-02006-8. View

2.
Moin A, Sathyapalan T, Atkin S, Butler A . Inflammatory Markers in Non-Obese Women with Polycystic Ovary Syndrome Are Not Elevated and Show No Correlation with Vitamin D Metabolites. Nutrients. 2022; 14(17). PMC: 9459875. DOI: 10.3390/nu14173540. View

3.
Sathyapalan T, Al-Qaissi A, Kilpatrick E, Dargham S, Atkin S . Anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017; 88(2):258-262. DOI: 10.1111/cen.13517. View

4.
Armanini D, Boscaro M, Bordin L, Sabbadin C . Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. Int J Mol Sci. 2022; 23(8). PMC: 9030414. DOI: 10.3390/ijms23084110. View

5.
Suhre K, Arnold M, Mukund Bhagwat A, Cotton R, Engelke R, Raffler J . Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun. 2017; 8:14357. PMC: 5333359. DOI: 10.1038/ncomms14357. View